Physician profile
Pardeep Rihal
NPI 1982671632
$84,971.90
in general payments reported to CMS, 2019-2025
35 companies · $8,655 in 2025
The $8,655 reported for 2025 was more than what 87% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $6,819 · 2021: $11K · 2022: $13K · 2023: $14K · 2024: $8,254 · 2025: $8,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $9,002 · Travel and Lodging: $675 · Education: $11.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,450.00 |
| Food and Beverage | $9,001.63 |
| Travel and Lodging | $675.29 |
| Education | $11.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $72,018.52 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $2,510.17 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,754.07 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Optinose US, INC. | $998.54 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $717.12 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $568.94 | 2019-2025 | |
| Blueprint Medicines Corporation | $560.43 | 2023-2025 | Ayvakit |
| Pfizer INC. | $540.66 | 2019-2024 | |
| Genentech USA, INC. | $493.01 | 2019-2024 | Xolair |
| Incyte Corporation | $438.38 | 2021-2025 | Opzelura |
| Grifols USA, LLC | $434.47 | 2022-2025 | Xembify |
| Csl Behring | $394.11 | 2019-2025 | Haegarda |
| Organon LLC | $349.32 | 2025 | Vtama |
| Alk-Abello, INC | $321.59 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $300.07 | 2025 | Neffy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $286.32 | 2019-2025 | |
| Abbvie INC. | $271.05 | 2022-2023 | Rinvoq |
| Genentech, INC. | $267.09 | 2022-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $256.33 | 2021-2024 | Gattex |
| Teva Pharmaceuticals USA, INC. | $239.59 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $206.09 | 2021-2023 | Orladeyo |
| Galderma Laboratories, L.P. | $156.74 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.47 | 2020-2022 | |
| Cycle Pharmaceuticals INC | $134.60 | 2024-2025 | Sajazir |
| Shire North American Group INC | $108.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $91.44 | 2019-2021 | |
| Amgen INC. | $83.65 | 2020-2022 | |
| Ethicon US, LLC | $83.37 | 2022 | |
| Phadia US INC. | $74.93 | 2022 | |
| Kaleo, INC. | $45.88 | 2021-2023 | Auvi-Q |
| Circassia INC. | $45.49 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $21.28 | 2025 | Alvesco |
| Ionis Pharmaceuticals, INC. | $19.52 | 2025 | |
| Tersera Therapeutics LLC | $16.55 | 2025 | Quzyttir |
| Covis Pharma Gmbh | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pardeep Rihal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.